Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $21.71 Average Price Target from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been assigned an average rating of “Buy” from the nine research firms that are presently covering the stock, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $22.14.

A number of research analysts have recently issued reports on ZVRA shares. Guggenheim lifted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday. Canaccord Genuity Group lifted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price target on shares of Zevra Therapeutics in a report on Wednesday, March 12th.

Insiders Place Their Bets

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the sale, the chief financial officer now owns 51,361 shares of the company’s stock, valued at approximately $403,697.46. The trade was a 17.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Neil F. Mcfarlane sold 61,273 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the sale, the chief executive officer now directly owns 222,060 shares of the company’s stock, valued at $1,745,391.60. This represents a 21.63 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 85,773 shares of company stock valued at $674,176. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ZVRA. Simplify Asset Management Inc. acquired a new position in shares of Zevra Therapeutics in the 3rd quarter valued at $833,000. Intech Investment Management LLC acquired a new position in shares of Zevra Therapeutics in the 3rd quarter valued at $95,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Zevra Therapeutics by 10.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,356 shares of the company’s stock valued at $842,000 after buying an additional 11,038 shares during the period. Valence8 US LP acquired a new position in shares of Zevra Therapeutics in the 3rd quarter valued at $150,000. Finally, FMR LLC grew its holdings in shares of Zevra Therapeutics by 282,687.5% in the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock valued at $16,054,000 after buying an additional 2,312,384 shares during the period. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $8.31 on Wednesday. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76. The firm has a 50 day moving average of $7.93 and a 200-day moving average of $8.16. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $449.70 million, a P/E ratio of -4.22 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. As a group, sell-side analysts anticipate that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.